Solara Active Pharma Sciences Ltd. · NSE:SOLARA
Solara Active Pharma Sciences — Q3 FY2019 Earnings Presentation
10 slides from Solara Active Pharma Sciences's earnings presentation, Jan 31, 2019
Slide 1: Q3 FY19 Earnings Presentation, January 31, 2019
RESPECT INTEGRITY TRANSPARENCY EFFICIENCY J A N U A R Y 3 1 , 2 0 1 9
Slide 2: Key Highlights for the quarter
Key Highlights for the quarter “ Quarterly Update(QoQ) Quarterly Update(YoY) 9MFY19 Update(YoY) • Total Revenue was ₹3,601 Mn for • Total Revenue was ₹3,601 Mn for • Total Revenue was ₹10,071 Mn for Q3FY19 as compared to ₹3,437 Q3FY19 as compared to ₹2,361 9MFY19 as compared to ₹7,498 We are pleased
Slide 3: Key Business Highlights for the quarter
Key Business Highlights for the quarter Base Business Split by End-Geography » During Q3FY19, Base business grew by 3% over Q2FY19. North North » Growth in base business emanated from both volume America , America , ROW, 24% 36% ROW, 23% 37% and price. » Top 10 Customer account for 55% revenues whil
Slide 4: Q3FY19 Performance - QoQ
Q3FY19 Performance - QoQ Financial Highlights Quarterly Trend Particulars Q3 FY19 Q2 FY19 QoQ Revenues Operating EBITDA Reported EBITDA Revenue 3,601 3,437 5% 3,601 3,437 Operating EBITDA 757 669 13% OP EBITDA Margins 21.0% 19.5% 150 bps R&D Cost -104 -111 757 656 669 494 Forex gain/(Loss) 3 -64 Rep
Slide 5: Q3FY19 Performance - YoY
Q3FY19 Performance- YoY Financial Highlights Quarterly Trend Particulars Q3 FY19 Q3 FY18 YoY Revenues Operating EBITDA Reported EBITDA Revenue 3,601 2,361 53% 3,601 Operating EBITDA 757 235 222% 2,361 OP EBITDA Margins 21.0% 10.0% 1100 bps R&D Cost -104 -53 757 656 Forex gain/(Loss) 3 47 235 229 Rep
Slide 6: 9MFY19 Review
9MFY19 Review Financial Highlights 9M Trend Particulars 9MFY19 9MFY18 Change Revenues Operating EBITDA Reported EBITDA Revenue 10,071 7,498 34% 2,057 1,066 93% 10,071 Operating EBITDA OP EBITDA Margins 20.4% 14.2% 620 bps 7,498 R&D Cost -312 -75 Forex gain/(Loss) -129 49 Reported EBITDA 1,615 1,040
Slide 7: Corporate Update
Corporate Update “ Key Updates » The board of directors at their meeting held today also approved an aggregate fundraising of ₹4,600 Mn over a period of 18 months from the Promoters’ Group and TPG Growth IV SF Pte. Ltd. (TPG Growth ) through allotment of convertible warrants. The proposed investment
Slide 8: About Solara
About Solara API only business model with large scale infrastructure, wide products and established customer relationships Capabilities Research Complex chemistry capabilities including Pipeline of 20+ products under handling of catalytic hydrogenation, hydride different stages of development reduct
Slide 9: Solara - 5 years perspective
Solara- 5 years perspective Business Continuity Portfolio of new products and new customers to augment current base and enable steady growth Worldwide Presence Well on its path to become a Established strongholds in key regulated markets and growth territories leading pure-play API company with focu
Slide 10: Registered Office
REGISTERED OFFICE 201, Devavrata, Sector 17, Vashi, Navi Mumbai - 400 703. Tel.: +91 22 2789 2924 Fax No. +91 22 2789 2942 Email: investors@solara.co.in Website: www.solara.co.in CIN: U24230MH2017PLC291636 CORPORATE OFFICE 3rd & 4th Floor, Batra Centre, No.28, Sardar Patel Road, Guindy, Chennai - 60
Solara Active Pharma Sciences — Q3 FY2019 Earnings Presentation on 6ix